Hutchison MediPharma (HMP) is a novel drug R&D company focusing on discovering, developing and commercializing innovative therapeutics in oncology and autoimmune diseases. With a team of around 300 scientists and staff, our pipeline is comprised of novel oral compounds for cancer and inflammation in development in North America, Europe, Australia and China.
Founded in 2002, HMP's strategic partnerships involve global, innovative companies such as AstraZeneca, Eli Lilly, Janssen and Nestlé Health Science in oncology and inflammation research & development.
HMP is a subsidiary of Chi-Med (Hutchison China MediTech).
|
|
|
1-10 employees
View all Hutchison MediPharma employees
|
|
Pharmaceuticals
|
|
Building 4, 917 Halei Road,,Shanghai,Shanghai,CN
|
|
2002
|
|
Biotechnology, Pharmaceuticals, Research, Oncology, Ibd, China, Development, Pharma, Biotech, Shanghai, Cancer, Botanicals, Drugs, Inflammation, Lymphoma, Autoimmune Disease, Kinase Inhibitors, Targeted Therapies, Tumors, Nce
|
Samantha Du is the CEO of Hutchison MediPharma. To contact Samantha Du email at [email protected].
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.